Assess whether scientific advice should be sought before the next trial

Situation

An inspector asking for batch records you cannot produce this week put 505(b)(2) literature-to-product bridge table in front of CMC change-control owner in a safety team sitting on a new disproportionate signal. This Pharma & Life Sciences / Clinical and Evidence Strategy close is scientific advice should be from 505(b)(2) literature-to-product bridge table, and the live options are Proceed under protocol, Pause the pathway, Escalate safety review.

Decision

CMC change-control owner in a safety team sitting on a new disproportionate signal must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.

Hypotheses to test

• CMC change-control owner can defend Proceed under protocol from 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week in a Pharma & Life Sciences challenge.
• CMC change-control owner cannot defend Proceed under protocol from 505(b)(2) literature-to-product bridge table; Pause the pathway is what the extract actually supports after an inspector asking for batch records you cannot produce this week.
• An inspector asking for batch records you cannot produce this week never reached the population in 505(b)(2) literature-to-product bridge table — reopen intake, do not close scientific advice should be.
• Two facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week conflict for CMC change-control owner; hold this Clinical and Evidence Strategy file.

Analysis required

• Check whether 505(b)(2) literature-to-product bridge table supports the labeled claim CMC change-control owner would keep.
• Map FDA-response timing and owner in a safety team sitting on a new disproportionate signal.
• Trace CMC, labeling, or pharmacovigilance facts in 505(b)(2) literature-to-product bridge table after an inspector asking for batch records you cannot produce this week.
• For this Pharma & Life Sciences Clinical and Evidence Strategy file, read 505(b)(2) literature-to-product bridge table against an inspector asking for batch records you cannot produce this week and write the one fact that would move scientific advice should be for CMC change-control owner.